colitis and glp-1 SAFETY CLINICAL EFFECTIVENESS OF GLP1 AGONISTS IN INFLAMMATORY BOWEL DISEASE PATIENTS GLP-1 Receptor Agonists in Obese

Those tracking peptides for muscle growth alongside their GLP-1 protocol understand that protecting existing muscle is just as important as losing fat

Nonetheless, published data suggest outcomes are still poor: FormBlends observed that only 32% of initial Wegovy PAs went through (68% denied) at Express Scripts in 202425 data ( [3] )

The most symptoms reported represent those already known from clinical trials, gastrointestinal issues, as reported by 43.5% of users

More specifically, among these cases, 19 (48.7%) were associated with liraglutide, 9 (23.1%) with dulaglutide, 4 (10.3%) each with exenatide and semaglutide, while 1 (2.6%) case each was linked to lixisenatide, albiglutide, and tirzepatide